【简单介绍】
【详细说明】
日度归档：2025年5月13日
Merck Millipore Fluoropore表面过滤膜PTFE疏水FGLP02500
【简单介绍】
【详细说明】
Whatman6710-7502Polycap TF囊式过滤器POLYCAP 75 0.2 PTFE 1/PK B/B
【简单介绍】
【简单介绍】
【详细说明】
上海金畔生物科技有限公司
文章号19774584-19774584
MSSI (PMEI)
MSSI (PMEI)
货号：
ER1342
品牌：
MBI
产品简介
| 单位 | 支 |
| 规格 | 1250U (5U/ul) |
应用：DNA&基因组测序分析、PCR
5-溴-4-氯-3-吲哚-beta-D-半乳糖苷X-gal
5-溴-4-氯-3-吲哚-beta-D-半乳糖苷X-gal
货号： BS139-1g
规格：1g
品牌： Jinpan
| 货号 | BS139-1g |
| 规格 | 1g |
| 品牌 | Jinpan |
AnaSpec品牌代理商
上海金畔生物科技有限公司是AnaSpec品牌代理商 ，欢迎访问官网了解更多产品信息和订购。
AnaSpec
简要描述：
AnaSpec是一家由多肽合成、荧光标记、抗体、树脂合成专家团队组成的生物企业，为科研工作者提供全套的蛋白质组学研究解决方案。
AnaSpec是一家由多肽合成、荧光标记、抗体、树脂合成专家团队组成的生物企业，为科研工作者提供全套的蛋白质组学研究解决方案。
产品线主要分三个部分：多肽、检测试剂和树脂等化学试剂，适合基础研究、高通量筛选和药物发现等方面；还提供多肽合成、抗体生产和分析试剂盒开发。能合成不同数量级（mg-g级）的多种长度序列肽，常规合成肽为50个氨基酸或更长。
Established in 1993, AnaSpec, Inc. is a leading provider of integrated proteomic and genomic solutions™ for worldwide life science research. As a subsidiary of Kaneka Eurogentec S.A., AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, oligonucleotides, and qPCR kits. Our broad product line of catalog and custom biochemicals and reagents, are used by scientists for basic research, high-throughput screening, and drug discovery. AnaSpec's premier custom services include peptide synthesis, assay development, antibody production, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.
|
品牌 |
名称 |
1 |
AS-63694 |
0.1 mg |
|
AnaSpec |
Apidaecin IB |
3 |
AS-64906 |
1mg |
|
AnaSpec |
Biotin – LC – LL – 37 |
5 |
AS-24009 |
0.5 mg |
|
AnaSpec |
CSP – 2, Competence – Stimulating Peptide – 2 |
7 |
AS-61001 |
1 mg |
|
AnaSpec |
LL – 37, reverse sequence |
9 |
AS-65455-5 |
5mg |
|
AnaSpec |
Adrenomedullin (22 – 52), human |
11 |
AS-60454 |
0.5 mg |
|
AnaSpec |
[NMeG24, NMeI26] Human Islet Amyloid Polypeptide (IAPP) (22 – 27) |
13 |
AS-60804 |
1 mg |
|
AnaSpec |
Amylin (1 – 37), human, amide |
15 |
AS-60253-1 |
1mg |
TLR7/8 激动剂及相关产品
TLR7/8 激动剂及相关产品
TLR7和TLR8都是与病毒感染引起的免疫反应相关的胞内受体。它们识别富含GU的短单链RNA，以及咪唑喹啉和核苷类似物等人工合成的小分子。TLR7/TLR8的信号通路依赖于MyD-88的活化、AP-1和IFN-α/β等转录因子入核，以及IRF7的磷酸化。IRF7磷酸化诱导ISRE的表达和I型干扰素基因的产生，而AP-1和IFN-α/β的激活导致细胞因子的释放。
TLR7/8 激动剂相关产品：
|
PRODUCT |
ORIGIN/DESCRIPTION |
GRADE* |
WORKING CONCENTRATION |
QTY |
CATALOG CODE |
|
TLR7 Agonists |
|||||
|
CL264 |
Adenine analog |
TLR2 – /TLR4 – |
50 ng – 10 µg/ml |
500 µg 5 mg |
tlrl-c264e tlrl-c264e-5 |
|
CL307 |
Hydroxyadenine spermine compound |
TLR2 – /TLR4 – |
5 ng – 1 µg/ml |
500 µg |
tlrl-c307 |
|
CL347 – AdiFectin™ |
Hydroxyadenine spermine compound |
TLR2 – /TLR4 – |
300 ng – 3 µg/ml |
500 µg |
tlrl-c347 |
|
CL401 |
PAM2C-conjugated hydroxyadenine compound |
TLR2 + /TLR4 – |
1 ng – 10 µg/ml |
500 µg |
tlrl-c401 |
|
CL401 VacciGrade™ |
Preclinical grade CL401 |
VacciGrade™ |
20 – 50 µg/mouse |
1 mg |
vac-c401-5 |
|
CL413 – Adilipoline™ |
PAM2CK4-conjugated hydroxyadenine compound |
TLR2 + /TLR4 – |
50 pg – 10 µg/ml |
500 µg |
tlrl-c413 |
|
TLR7 Agonists |
|||||
|
CL413 VacciGrade™ |
Preclinical grade CL413 |
VacciGrade™ |
20 – 50 µg/mouse |
5 mg |
vac-c413-5 |
|
CL531 |
PAM2CK4-conjugated hydroxyadenine compound |
TLR2 +/ TLR4 – |
5 pg – 10 µg/ml |
500 µg |
tlrl-c531 |
|
CL572 |
Monoacyl-ethyl-cystein hydroxyadenine compound |
TLR2 +/ TLR4 – |
0.5 ng – 1 µg/ml |
500 µg |
tlrl-c572 |
|
Gardiquimod™ |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
0.1 – 3 µg/ml |
500 µg 5 mg |
tlrl-gdqs tlrl-gdq-5 |
|
Imiquimod (R837) |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
1 – 5 µg/ml |
500 µg 5 mg |
tlrl-imqs tlrl-imq |
|
Imiquimod VacciGrade™ |
Preclinical grade Imiquimod |
TLR2 -/ TLR4 – |
10 – 100 µg/mouse |
5 mg |
vac-imq |
|
Loxoribine |
Guanosine analog |
TLR2 -/ TLR4 – |
1 mM (300 µg/ml) |
50 mg |
tlrl-lox |
|
TLR8 Agonists |
|||||
|
ORN06/LyoVec™ |
ssRNA with 6 UUGU repeats / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-orn6 |
|
ssPolyU Naked |
RNA homopolymer |
TLR2 -/ TLR4 – |
1 – 10 µg/ml |
10 mg 10 x 10 mg |
tlrl-sspu tlrl-sspu-100 |
|
ssPolyU/LyoVec™ |
RNA homopolymer / LyoVec™ |
TLR2 -/ TLR4 – |
1 – 10 µg/ml |
4 x 25 µg |
tlrl-lpu |
|
ssRNA40/LyoVec™ |
HIV-1 LTR-derived ssRNA / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-lrna40 |
|
ssRNA41/LyoVec™ |
ssRNA40 control / LyoVec™ |
TLR2 -/ TLR4 – |
0.25 – 5 µg/ml |
4 x 25 µg |
tlrl-lrna41 |
|
TL8-506 |
Benzoazepine analog |
TLR2 -/ TLR4 – |
10 – 100 ng/ml |
500 µg |
tlrl-tl8506 |
|
TLR7/8 Agonists |
|||||
|
CL075 |
Thiazoquinoline compound |
TLR2 -/ TLR4 – |
100 ng – 5 µg/ml |
500 µg 5 mg |
tlrl-c75 tlrl-c75-5 |
|
CL097 |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
50 ng – 5 µg/ml |
500 µg 5 mg |
tlrl-c97 tlrl-c97-5 |
|
Poly(dT) |
Thymidine homopolymer ODN (17 mer) |
TLR2 -/ TLR4 – |
10 µM |
100 nmol |
tlrl-pt17 |
|
R848 (resiquimod) |
Imidazoquinoline compound |
TLR2 -/ TLR4 – |
10 ng – 10 µg/ml |
500 µg 5 mg |
tlrl-r848 tlrl-r848-5 |
|
R848 VacciGrade™ |
Preclinical grade R848 |
VacciGrade™ |
10 – 100 µg/mouse |
5 mg |
vac-r848 |
更多详情请咨询Invivogen代理商-上海金畔生物
D-海藻糖,D-(+)-Trehalose dihydrate,CAS：6138-23-4,货号：G8570-10g
D-海藻糖,D-(+)-Trehalose dihydrate,CAS：6138-23-4,货号：G8570-10g
| 市场价： | ￥150.0 | |
| 价格： |
|
|
| 品牌： | solarbio | |
| 规格： | 10g |
|
产品详情
说明书下载
参考文献
|
阿利克仑
阿利克仑
货号：
IA3120
品牌：
Jinpan
暂无详情
产品简介
| EC | EINECS 605-672-4 |
| MDL | MFCD09839018 |
| 描述 | 是肾素抑制剂。 |
| 别名 | 阿里斯基伦;CGP-60536 |
| 英文名称 | Aliskiren |
| CAS | 173334-57-1 |
| 分子式 | C30H53N3O6 |
| 分子量 | 551.76 |
| 纯度 | ≥98% |
| 单位 | 瓶 |
| 生物活性 | Aliskiren is the fourth class of pharmacological agents that modify the function of RAAS. It is an octanamide, is the first known representative of a new class of completely nonpeptide, low-molecular-weight, orally active transition-state renin inhibitors. [1] |
| In Vitro | Aliskiren has good water solubility and low lipophilicity, and is resistant to biodegradation by peptidases in the intestine, blood circulation, and the liver. Aliskiren has 10,000-fold higher affinity for renin than for other aspartic peptidases[1]. |
| In Vivo | In short-term studies, Aliskiren is effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. Aliskiren has a half-life of approximately 40 h, making it suitable for once-daily dosing, with less potential for loss of efficacy between doses than shorter acting agents. Aliskiren exhibits oral bioavailability due to its low molecular weight (609.8 Da) and nonpeptide structure, making it more resistant to gastrointestinal enzyme disintegration. However, it is still poorly absorbed (oral bioavailability, ～2.5%). Aliskiren is 50% protein bound, and the apparent volume of distribution is 135 L. Aliskiren is slightly metabolized in humans (about 20%) and is approximately 50% metabolized in rodents. Aliskiren effectively reduces functional plasma renin activity by binding to renin with high affinity, preventing it from converting angiotensinogen to angiotensin I. The inhibition of renin by aliskiren is associated with a reduction in circulating levels of angiotensin I and II, with a resultant increase in plasma renin concentration and inhibit activation of mitogen-activated protein kinases ERK1 (p44) and ERK2 (p42). It prevents hypertrophy and proliferation. Aliskiren is well tolerated, with the most common adverse events reported as headache, dizziness, and fatigue[1]. |
| SMILES | COCCCOC1=CC(C[C@@H](C[C@@H]([C@H](C[C@H](C(NCC(C)(C(N)=O)C)=O)C(C)C)O)N)C(C)C)=CC=C1OC |
| 靶点 | Renin |
| 数据来源文献 | [1] Pranay Wal, et al. J Pharm Bioallied Sci. 2011, 3(2): 189–193. |
| 规格 | 50mg 100mg |
是一种肾素抑制剂，具有降压活性。
ab16832-Rabbit polyclonal to c-Kit-Abcam原装-琼脂糖
【简单介绍】
【详细说明】
